NCT04531046View on ClinicalTrials.gov

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

April 19, 2022

Study Completion Date

June 30, 2026

Conditions
B-Cell Lymphoma RefractoryB-cell Lymphoma Recurrent
Interventions
DRUG

axicabtagene ciloleucel

Patient-specific (autologous) product cryopreserved in cryostorage bag

Trial Locations (16)

4000

CH Liège, Liège

21000

CHU de Dijon - Hôpital le Bocage, Dijon

34295

Hôpital Saint Eloi, Montpellier

35003

CHU de Rennes - Hôpital de Pontchaillou, Rennes

44093

CHU de Nantes - Hôtel Dieu, Nantes

54511

CHU Brabois, Vandœuvre-lès-Nancy

59037

Hôpital Claude Huriez, Lille

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

75475

APHP - Hôpital Saint Louis, Paris

Unknown

CHU de Bordeaux - Hôpital Haut Lévêque, Bordeaux

CHU Clermont Ferrand - Hôpital Estaing, Clermont-Ferrand

APHP - Hôpital Henri Mondor, Créteil

Hopital La Pitié Salpétriere, Paris

Hôpital Saint Antoine, Paris

IUCT Oncopole, Toulouse

Institut de Cancérologie Gustave Roussy, Villejuif

All Listed Sponsors
lead

The Lymphoma Academic Research Organisation

OTHER